Moderate

Idiopathic pulmonary fibrosis (IPF) & progressive pulmonary fibrosis

Interstitial lung disease · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

IPF is a chronic, progressive fibrosing interstitial pneumonia of unknown cause, limited to the lungs, with a radiological/histological UIP pattern and a median survival of ~3–5 years untreated. It typically affects adults > 60, more often men and ever-smokers, presenting with progressive exertional breathlessness, a dry cough, bibasal fine “Velcro” crackles and finger clubbing. “Progressive pulmonary fibrosis (PPF)” is the 2022 label for any NON-IPF interstitial lung disease (e.g. connective-tissue-disease ILD, hypersensitivity pneumonitis, unclassifiable ILD) that behaves like IPF and keeps progressing despite management — it is managed on the same antifibrotic principles.

Red flags

  • Rapidly worsening breathlessness or new hypoxaemia over days–weeks → suspect ACUTE EXACERBATION (see separate protocol), infection or PE
  • Resting hypoxaemia / exertional desaturation needing oxygen
  • Falling FVC or DLCO on serial testing (disease progression)
  • Signs of pulmonary hypertension or right-heart failure
  • New or growing lung nodule/mass (lung-cancer risk)

Assessment

Differential diagnosis

  • Connective-tissue-disease ILD (RA, systemic sclerosis, myositis/anti-synthetase)
  • Chronic hypersensitivity pneumonitis
  • Asbestosis / pneumoconiosis
  • Drug-induced ILD (amiodarone, methotrexate, nitrofurantoin, immunotherapy)
  • Sarcoidosis (fibrotic)
  • NSIP and other idiopathic interstitial pneumonias
  • Chronic heart failure / pulmonary oedema
  • Combined pulmonary fibrosis & emphysema (CPFE)

Investigations

  • High-resolution CT (HRCT) chest — the key test: a definite UIP pattern is subpleural, basal-predominant reticulation with honeycombing ± traction bronchiectasis and little ground-glass.
  • Full pulmonary function tests — restrictive pattern (reduced FVC & TLC) with a reduced DLCO; used as the baseline to track progression.
  • Bloods to exclude a cause: ANA, ENA, RF, anti-CCP, myositis panel (anti-Jo-1/anti-synthetase, anti-MDA5), anti-MCV; precipitins / exposure history for hypersensitivity pneumonitis.
  • Resting + exertional oximetry / 6-minute walk test (desaturation, oxygen need, prognosis).
  • MULTIDISCIPLINARY DISCUSSION (MDD) — respiratory, radiology and histopathology together make the diagnosis.
  • Where HRCT is not definite: transbronchial lung CRYOBIOPSY (2022 guideline — an acceptable alternative to surgical lung biopsy in centres with expertise) ± a genomic classifier; surgical lung biopsy if still unclassified.
  • Echocardiography for pulmonary hypertension if DLCO is disproportionately low or there is unexplained desaturation.

Management

  • Make the diagnosis through MDD and classify IPF vs another ILD (PPF) — this determines drug choice and eligibility.
  • Start an ANTIFIBROTIC early in IPF to slow FVC decline — pirfenidone OR nintedanib (either; choose by side-effect profile, comorbidity and patient preference). Do not wait for severe disease.
  • For NON-IPF ILD that is progressing (PPF): add nintedanib (conditionally recommended, 2022 guideline; INBUILD trial) alongside treatment of the underlying disease; antifibrotics complement, not replace, immunosuppression in CTD-ILD.
  • Supportive care for ALL: pulmonary rehabilitation, ambulatory/long-term oxygen for resting or exertional hypoxaemia, annual influenza + pneumococcal + COVID vaccination, and smoking cessation.
  • Do NOT start antacid medication or anti-reflux surgery solely to change IPF outcomes (2022 guideline — conditional recommendations AGAINST); treat symptomatic GORD on its own merits.
  • Refer for LUNG TRANSPLANT assessment EARLY (at diagnosis of IPF where appropriate) — it is the only intervention that improves survival; do not wait for end-stage disease.
  • Treat comorbidities: pulmonary hypertension (consider inhaled treprostinil for ILD-associated PH — INCREASE trial), GORD, OSA, emphysema, depression; screen for lung cancer (increased risk).
  • Introduce palliative/supportive care in parallel: treat refractory breathlessness (low-dose opioids) and cough, and start advance-care planning — prognosis is limited.
  • Monitor every 3–6 months with symptoms, FVC and DLCO; a falling FVC (≥ 5–10%) signals progression and prompts escalation or transplant discussion.

Drugs & doses

Pirfenidone — oral antifibrotic (IPF)
Nintedanib — oral antifibrotic (IPF, PPF, and SSc-ILD)
Nerandomilast (Jascayd) — oral PDE4B inhibitor; FDA-approved Oct 2025 for IPF (newest option; availability varies by country)
Supplemental oxygen (ambulatory / long-term)
Inhaled treprostinil — for ILD-associated pulmonary hypertension
Low-dose morphine — refractory breathlessness (palliative)

Disposition

ILD/respiratory specialist clinic with antifibrotic initiation and monitoring; early lung-transplant referral; pulmonary rehabilitation; palliative-care involvement for symptom control and advance-care planning. Admit for acute exacerbation, severe hypoxaemia or complications.

Complications & pitfalls

  • Progressive respiratory failure
  • Acute exacerbation of IPF (high mortality)
  • Pulmonary hypertension & cor pulmonale
  • Lung cancer
  • Venous thromboembolism
  • Secondary infection
  • Profound deconditioning and weight loss

Exam pearls

  • Bibasal fine “Velcro” inspiratory crackles + clubbing + progressive dry cough in an older adult = get an HRCT and think IPF.
  • Antifibrotics (pirfenidone, nintedanib) SLOW the rate of lung-function decline — they do not reverse fibrosis; start early and keep going even as FVC falls.
  • Nintedanib is the antifibrotic that also covers progressive non-IPF fibrosis (PPF) and scleroderma-ILD.
  • 2022 guideline reversed older advice: do NOT give antacids or anti-reflux surgery just to treat IPF.
  • Refer for lung transplant at diagnosis where appropriate — it is the only survival-improving option and waiting lists are long.
  • Newest option (2025): nerandomilast/Jascayd, a PDE4B inhibitor shown to add benefit even on top of existing antifibrotics.

Diagnose IPF (vs other progressive fibrotic ILD) by HRCT and MDD; start an antifibrotic (pirfenidone or nintedanib) EARLY to slow FVC decline, add pulmonary rehab, oxygen, vaccination and smoking cessation, refer for transplant early, and treat comorbidities and symptoms. Nintedanib also covers progressive pulmonary fibrosis (PPF); nerandomilast (Jascayd) is a newly FDA-approved (2025) PDE4B inhibitor. Do not use antacids/anti-reflux surgery to treat IPF itself.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.